LAPC

FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Retrieved on: 
Mittwoch, August 25, 2021
Company, European Economic Area, Astellas Pharma, Quality of life, CTGF, Therapy, Cancer, U.S. Securities and Exchange Commission, Commonwealth, Incidence, Erythropoiesis, Dialysis, GLOBE, SEC, CIA, IPF, Duchenne muscular dystrophy, DMD, Anemia, MDS, Chronic kidney disease, NDD, Review, Risk, MPH, NASDAQ, CKD, Pamrevlumab, Safety, LAPC, Adult, Patient, Erythropoietin, Idiopathic pulmonary fibrosis, SAN, Microdeletion syndrome, HIF, Pancreatic cancer, Annual report, AstraZeneca, Security (finance), Pharmaceutical industry, Medical device

WHITNEY is a Phase 2, open label study investigating the efficacy and safety of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies.

Key Points: 
  • WHITNEY is a Phase 2, open label study investigating the efficacy and safety of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies.
  • Roxadustat is a promising new approach for treating chemotherapy induced anemia, which complicates the treatment of many cancer patients, said Mark D. Eisner, MD, MPH, Chief Medical Officer, FibroGen.
  • Further studies will be necessary to evaluate whether roxadustat can effectively and safely treat this important type of anemia.
  • Roxadustat is also in clinical development for anemia of chronic kidney disease (CKD) and anemia associated with myelodysplastic syndromes (MDS).

FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer

Retrieved on: 
Montag, August 16, 2021
HIF, Pamrevlumab, Monterrey Institute of Technology and Higher Education, NASDAQ, U.S. Securities and Exchange Commission, Business development, CIA, CEO, Strategic planning, SAN, Company, Idiopathic pulmonary fibrosis, Science, LAPC, Technology, DMD, IPF, GLOBE, Duchenne muscular dystrophy, Mergers & Acquisitions, SEC, Mergers and acquisitions, Roxadustat, Pancreatic cancer, Retirement, Annual report, Security (finance), Â, Patient, CTGF, Microdeletion syndrome, Leadership, MDS, Chronic kidney disease, Risk, Anemia, Safety, Therapy, Business, Johnson & Johnson, CKD, Business administration, Management, Pharmaceutical industry

SAN FRANCISCO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role.

Key Points: 
  • SAN FRANCISCO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role.
  • Pat will continue as Chief Financial Officer through September 6, 2021, and will remain with FibroGen through March 31, 2022 serving as Executive Advisor to the CEO to ensure a smooth transition.
  • On behalf of the board, shareholders, and our employees, I want to thank Pat for his contributions as Chief Financial Officer and dedicated serviceover the past 21 years, said Enrique Conterno, Chief Executive Officer, FibroGen.
  • Juan Graham will become Chief Financial Officer effective September 7, 2021, overseeing all finance operations.

Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments

Retrieved on: 
Dienstag, August 10, 2021
Head, LAPC, Private Securities Litigation Reform Act, Large-cell lung carcinoma, HNC, Patient, FDA, Insurance, Survival, COVID-19, Pancreatic cancer, Esophagitis, Clinical trial, Ownership, Fast track (FDA), U.S. Securities and Exchange Commission, Nasdaq, Progression-free survival, Investment, Safety, GC4419, Privacy, AESOP, Growth, SEC, Lung cancer, Data analysis, Incidence, Blackstone, Health, GLOBE, Mucositis, Therapy, Annual report, SBRT, NSCLC, Cancer, Company, SOM, Radiation, Research, CEO, Pharmaceutical industry, Tutoring

MALVERN, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2021, and highlighted recent corporate accomplishments.

Key Points: 
  • The Company expects to report topline data in the fourth quarter of 2021.
  • The Company expects to report final results from the trial, with at least one year of follow-up on all patients, in the third quarter of 2021.
  • Research and development expenses were $16.0 million in the second quarter of 2021, compared to $13.8 million for the same period in 2020.
  • General and administrative expenses were $5.1 million in the second quarter of 2021, compared to $3.9 million for the same period in 2020.